Ose Immunotherapeutics Sa (ORPOF)

$4.43 0.00 (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio N/A
Volume 3,500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts Strong Buy
Price Target N/A
BioTuesdays
BioTuesdays Feb. 24 at 4:57 PM
OSE Reports Phase 2 results for Lusvertikimab in UC presented at ECCO $ORPOF https://biotuesdays.com/2025/02/24/ose-reports-phase-2-results-for-lusvertikimab-in-uc-presented-at-ecco/
0 · Reply
BioTuesdays
BioTuesdays Nov. 4 at 4:05 PM
OSE Immunotherapeutics has announced positive results from the induction period its Phase 2 study of Lusvertikimab (OSE-127), demonstrating strong efficacy and a favorable safety profile in patients with moderate to severe active ulcerative colitis (UC) $ORPOF https://biotuesdays.com/2024/11/04/ose-announces-positive-phase-2-results-of-lusvertikimab-for-uc/
0 · Reply
yus37
yus37 Oct. 10 at 4:11 PM
$ORPOF $ABBV $XBI OSE Pharma has been flying under the radar while teaming up with AbbVie, Boehringer Ingelheim, Veloxis Pharmaceuticals, and CKD. These partnerships could lead to up to €2.1 billion in milestone payments, including €180 million already received.
0 · Reply
BioTuesdays
BioTuesdays Oct. 1 at 1:46 PM
OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies $ORPOF https://biotuesdays.com/2024/10/01/ose-immunotherapeutics-breaking-through-the-therapeutic-ceiling-with-first-in-class-immunotherapies/
0 · Reply
XxGodFatherxX
XxGodFatherxX Mar. 22 at 5:59 PM
$ORPOF 🤔
1 · Reply
Latest News on ORPOF
No data available.
BioTuesdays
BioTuesdays Feb. 24 at 4:57 PM
OSE Reports Phase 2 results for Lusvertikimab in UC presented at ECCO $ORPOF https://biotuesdays.com/2025/02/24/ose-reports-phase-2-results-for-lusvertikimab-in-uc-presented-at-ecco/
0 · Reply
BioTuesdays
BioTuesdays Nov. 4 at 4:05 PM
OSE Immunotherapeutics has announced positive results from the induction period its Phase 2 study of Lusvertikimab (OSE-127), demonstrating strong efficacy and a favorable safety profile in patients with moderate to severe active ulcerative colitis (UC) $ORPOF https://biotuesdays.com/2024/11/04/ose-announces-positive-phase-2-results-of-lusvertikimab-for-uc/
0 · Reply
yus37
yus37 Oct. 10 at 4:11 PM
$ORPOF $ABBV $XBI OSE Pharma has been flying under the radar while teaming up with AbbVie, Boehringer Ingelheim, Veloxis Pharmaceuticals, and CKD. These partnerships could lead to up to €2.1 billion in milestone payments, including €180 million already received.
0 · Reply
BioTuesdays
BioTuesdays Oct. 1 at 1:46 PM
OSE Immunotherapeutics breaking through the therapeutic ceiling with first-in-class immunotherapies $ORPOF https://biotuesdays.com/2024/10/01/ose-immunotherapeutics-breaking-through-the-therapeutic-ceiling-with-first-in-class-immunotherapies/
0 · Reply
XxGodFatherxX
XxGodFatherxX Mar. 22 at 5:59 PM
$ORPOF 🤔
1 · Reply